Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Kelvin A. Moses, MD, PhD, discusses the prostate cancer treatment sipuleucel-T (Provenge). Moses is an associate professor of urology and fellowship director of urologic oncology at Vanderbilt University Medical Center, Nashville, Tennessee.

Related Videos
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Dr. Adam Murphy in an interview with Urology Times
Expert cardiologist
Expert urologist
Expert cardiologist
Expert urologist
Patient predictors of postprostatectomy incontinence | Image credit: © jakkapan - stock.adobe.com
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Expert urologist
Related Content
© 2023 MJH Life Sciences

All rights reserved.